Effects of p53 mutants derived from lung carcinomas on the p53-responsive element (p53RE) of the MDM2 gene

British Journal of Cancer

Volumn 77, Issue 3, 1998, Pages 374-384

  Gorgoulis, V G ^a,e   Zacharatos, P V ^a   Manolis, E ^a   Ikonomopoulos, J A ^a   Damalas, A ^a,b   Lamprinopoulos, C ^a   Rassidakis, G Z ^a   Zoumpourlis, V ^c   Kotsinas, A ^a   Rassidakis, A N ^a   Halazonetis, T D ^d   Kittas, C ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^c INSTITUTE OF BIOLOGY   (Greece)

^d WISTAR INSTITUTE   (United States)

^e NONE   (Greece)

Author keywords

Lung cancer; MDM2 gene; MDM2 isoforms; p53 mutations; p53 responsive element

Indexed keywords

MUTANT PROTEIN; PROTEIN P53;

AMINO ACID SUBSTITUTION; ARTICLE; CARCINOMA CELL; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CARCINOMA; MAJOR CLINICAL STUDY; PLASMID; PRIORITY JOURNAL; PROTEIN DNA BINDING; REPORTER GENE; TRANSACTIVATION;

EID: 14444269227     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.60     Document Type: Article

References (79)

1. Barak Y, Gottlieb E, Juven-Gershon T and Oren M (1994) Regulation of mdm2 expression by p53: alternative promoters produce transcripts with non identical translation potential. Genes Dev 8: 1739-1749
2. Bayle JH, Elenbaas B and Levine AJ (1995) The carboxyl-terminal domain of p53 protein regulates sequence-specific DNA binding through its non-specific nucleic acid-binding activity. Proc Natl Acad Sci USA 92: 5729-5733
3. Buckbinder L, Talbott R, Valesco-Miguel S, Takenaka I, Faha B, Seizinger BR and Kley N (1995) Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 377: 646-649
4. Bueso-Ramos CE, Yang Y, deLeon E, McCown P, Stass SA and Albitar M (1993) The human MDM2 oncogene is overexpressed in leukemias. Blood 82: 2617-2623
5. Bueso-Ramos CE, Manshouri T, Haidar M, Huh YO, Keating MJ and Albitar M (1995a) Multiple patterns of MDM2 deregulation in human leukemias: Implications in leukemogenesis and prognosis. Leuk Lymph 17: 13-18
6. Bueso-Ramos CE, Yang Y, Manshouri T, Feltz L, Ayala A, Glassman AB and Albitar M (1995b) Molecular abnormalities of MDM-2 in human sarcomas. Int J Oncol 7: 1043-1048
7. Bueso-Ramos CE, Manshouri T, Yang Y, McCown P, Ordonez NG, Sneige N and Albitar M (1996) Abnormal expression of multiple MDM-2 proteins in breast carcinomas. Breast Cancer Res Treat 85: 29-40
8. Chen JY, Funk DK, Wright WE, Shay JW and Minna JD (1993) Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences. Oncogene 8: 2159-2166
9. Chen X, Bargonetti J and Prives C (1995) p53 through p21 (WAF1/CIP1), induces cyclin D1 synthesis. Cancer Res 55: 4257-4263
10. Chin KV, Ueda K, Pastan I and Gottesman MM (1992) Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 255: 459-462
11. Cho Y, Gorina S, Jeffrey PD and Pavletich NP (1994) Crystal Structure of a p53 Tumour Suppressor-DNA Complex: Understanding Tumorigenic Mutations. Science 265: 346
12. Creighton TE (1984) Proteins Structures and Molecular Properties p. 235 WH Freeman:
13. Crook T, Marston NJ, Sara EA and Vousden KH (1994) Transcriptional activation by p53 correlates with suppression of growth but not transformation. Cell 79: 817-827
14. Dameron KM, Volpert OV, Tainsky MA and Bouck N (1994) Control of angiogenesis in fibroblast by p53 regulation of thrombospontin-1. Science 265: 1582-1584
15. Deb SP, Munoz RM, Brown DR, Subler MA and Deb S (1994) Wild-type human p53 activates the human epidermal growth factor receptor promoter. Oncogene 9: 1341-1349
16. Deng EC and Nickoloff JA (1992) Site-directed mutagenesis of virtually any plasmid by eliminating a unique restriction site. Anal Biochem 20: 81
17. Deffie A, Wu H, Reinke V and Lozano G (1993) The tumor suppressor p53 regulates its own transcription. Mol Cell Biol 13: 3415-3423
18. Dittmer D, Parti S, Zambetti G, Chu S, Teresky AK, Moore M, Finlay C and Levine AJ (1993) Gain of function mutations in p53. Nature Genet 4(1): 42-46
19. El-Diery WS, Tokino T, Velculescu VE, Levy DB, Parson R, Trent GM, Lin D, Merker WE, Kinz KW and Volgenstein B (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825
20. Fontana X, Ferrari Abbes M, Monticelli Namer M and Bussiere F (1994) Etude de l'amplification du gene mdm-2 dans les tumeurs primitives du cancer du sein. Bull Cancer 81: 587
21. Foulkes WD, Stamp GWH, Afzal S, Lalani N, McFarlane CP, Trowsdale J and Campbell IG (1995) MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status. Br J Cancer 67: 551-559
22. Funk WD, Pak DT, Karas RH, Wright WE and Shay JW (1992) A transcriptonally active DNA-binding site for human p53 protein complexes. Mol Cell Biol 12: 2866-2871
23. Gorgoulis V, Zoumpourlis V, Rassidakis G, Karameris A, Barbatis C, Spandidos DA and Kittas C (1995a) Molecular analysis of p53 gene in laryngeal pre-malignant and malignant lesions: p53 protein immunohistochemical expression is positively related to proliferating cell nuclear antigen labelling index. Virchows Archiv 426: 339-344
24. Gorgoulis V, Sfikakis PP, Karameris A, Papastamatiou H, Trigidou R, Veslemes M, Spandidos DA, Sfikakis P and Jordanoglou J (1995b) Molecular and immunohistochemical study of class 1 growth factor receptors in squamous cell lung carcinomas. Path Res Pract 191: 973-981
25. Gorgoulis V, Rassidakis G, Karameris A, Papastamatiou H, Trigidou R, Veslemes M, Rassidakis A and Kittas C (1996a) Immunohistochemical and molecular evaluation of the MDM2 gene product in bronchogenic carcinoma. Mod Path 9: 544-554
26. Gorgoulis V, Zoumpourlis V, Rassidakis G, Karameris A, Rassidakis A, Spandidos DA and Kittas C (1996b) A molecular and immunohistochemical study of the MDM2 protein isoforms and p53 gene product in bronchogenic carcinoma. J Path 180: 129-137
27. Gottlieb TM and Oren M (1996) p53 in growth control and neoplasia. Biochim Biophys Acta 1287: 77-102
28. Greenblatt MS, Bennett WP, Hollstein M and Harris CC (1994) Mutations in the p53 tumour suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878
29. Grinsberg D, Mechta F, Yaniv M and Oren M (1991) Wild-type p53 can down-modulate the activity of various promoters. Proc Natl Acad Sci USA 88: 9979-9983
30. Halazonetis TD and Kandil AN (1993) Conformational shifts propagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants. EMBO J 12: 5057-5064
31. Hall P, Meek D and Lane DP (1996) p53-integrating the complexity. J Path 180: 1-5
32. Haupt T, Barak Y and Oren M (1996) Cell type specific inhibition of p53-mediated apoptosis by mdm2. EMBO J 15: 1596-1606
33. Hinds P, Finlay C and Levine AJ (1989) Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation. J Virol 63: 739-746
34. Hsiao M, Low J, Dorn E, Ku D, Pattengale P, Yeargin J and Haas M (1994) Gain of function mutations of the p53 gene induce lympohematopoietic metastasic potential and tissue invasiveness. Am J Pathol 145: 702-714
35. Kastan MB, Zhan Q, El-Diery WS, Carrier F, Jacks T, Walsh WV, Plunkett BS, Volgenstein B and Fornance AJ Jr (1992) A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telegiectasia. Cell 71: 587-597
36. Kawamura M, Yamashita T, Segawa K, Kaneuchi M, Shindoh M and Fujinaga K (1996) The 273rd codon mutants of p53 show growth modulation activities not correlated with p53-specific transactivation activity. Oncogene 12: 2361-2367
37. Ko LJ and Prives C (1996) p53: puzzle and paradigm. Genes Dev 10: 1054-1072
38. Levine AJ (1997) p53, the cellular gatekeeper for growth and devision. Cell 88: 323-331
39. Lin J, Teresky AK and Levine AJ (1995) Two critical hydrophobic amino acids in the N-terminal domain of the p53 protein are required for the gain of function phenotypes of human p53 mutants. Oncogene 10: 2387-2390
40. Mack DH, Vartikar J, Pipas JM and Laimins LA (1993) Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53. Nature 363: 281-283
41. Mackay B, Lukeman JM and Ordoñez N (1991) Tumors of the Lung WB Saunders: Philadelphia, USA
42. Martin DW, Munoz RM, Subler MA and Deb S (1993) p53 binds to the TATA-binding protein-TATA complex. J Biol Chem 268: 13062-13067
43. Martin K, Trouche D, Hagemeier C, Sorensen TS, La Thangue NB and Kouzarides T (1995) Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature 375: 691-694
44. Matlashewski G, Lamb P, Pim D, Peacock J, Crawford L and Benchimol S (1984) Isolation and characterization of a human p53 cDNA clone: expression of the human p53 gene. EMBO J 3: 3257-3262
45. Michalovitz D, Halevy O and Oren M (1991) p53 mutations: gain or losses? J Cell Biochem 45: 22-29
46. Milner J, Medcalf EA and Cook AC (1991). Tumor suppressor p53: analysis of wild type and mutant p53 complexes. Mol Cell Biol 11: 12-19
47. Miyashita T and Reed JC (1995) Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80: 293-299
48. Momand J, Zambetti GP, Olson DC, George D and Levine AJ (1992) The MDM2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-1245
49. Morris GF, Bischoff JR and Mathews MB (1996) Transcriptional activation of the human proliferating-cell nuclear antigen promoter by p53. Proc Natl Acad Sci 93: 895-899
50. Muller BF, Paulsen D and Deppert W (1996) Specific binding of MAR/ASAR DNA-elements by mutant p53. Oncogene 12: 1941-1952
51. Niewolik D, Vojtesek B and Kovarik J (1995) p53 derived from human tumour cell lines and containing distinct point mutations can be activated to bind its consensus target sequences. Oncogene 10: 881-890
52. Oca Luna RM, Wagner DS and Lozano G (1995) Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378: 203-205
53. Olson D, Marechal V, Momand J, Chen J, Romochi C and Levine AJ (1993) Identification and characterization of multiple mdm2 proteins and mdm2 p53 protein complexes. Oncogene 8: 2353-2360
54. Oren M and Prives C (1996) p53: upstream, downstream and offstream. Review of the 8th p53 workshop (Dundee, 5-9 July 1996). Biochim Biophys Acta 1288: R13-R19
55. Ory K, Legros Y, Auguin C and Soussi T (1994) Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. EMBO J 13: 3496-3504
56. Osifchin NE, Jiang D, Ohtani-Fujita N, Fujita T, Carroza M, Kim S-J, Sakai T and Robbins PD (1994) Identification of a p53 binding site in the human retinoblastoma susceptibility gene promoter. J Biol Chem 269: 6383-6389
57. Owen-Schaub LB, Zhang W, Cusack JC, Angelo LS, Santee SM, Fujiwara T, Roth JA, Deisseroth AB, Zhang W-W, Kruzel K and Radinsky R (1995) Wild type human p53 and a temperature sensitive mutant induce fas/APO1 expression. Mol Cell Biol 15: 3032-3040
58. Park DJ, Nakamura H, Chumakov AM, Said JW, Miller CW, Chen DL and Koeffler HP (1994) Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines. Oncogene 9: 1899-1906
59. Price BD and Park SJ (1994) DNA Damage Increases the Levels of MDM2 Messenger RNA in wtp53 Human Cells. Cancer Res 54: 896-899
60. Prices C (1994) How loops, β sheets, and α helices help us to understand p53. Cell 78: 543-546
61. Rowan S, Ludwig RL, Haupt Y, Bates S, Lu X, Oren M and Vousden H (1996) Specific loss of apoptotic but not cell cycle arrest function in a human tumor derived p53 mutant. EMBO J 15: 827-838
62. Sambrook J, Fritsh EF and Maniatis T (1989) Molecular Cloning. A Laboratory Manual. Cold Spring Harbor, NY, Cold Spring Harbor Laboratory Press
63. Santhanam U, Ray A and Sehgal PB (1991) Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product. Proc Natl Acad Sci USA 88: 7605-7609
64. Shin TH, Paterson AJ and Kudlow JF (1995) p53 stimulates transcription from the human transforming growth factor-a promoter: a potential growth-stimulatory role for p53. Mol Cell Biol 15: 4694-4701
65. Sigalas I, Calvert AH, Anderson JJ, Neal DE and Lunec J (1996) Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: Transforming ability and frequent detection in human cancer. Nature Med 2: 912-917
66. Spandidos DA, Zoumpourlis V, Zachos G, Toas SH and Halazonetis TD (1995) Specific recognition of a transcriptional element within the human H-ras protooncogene by the p53 tumour suppressor. Int J Oncol 7: 1029-1034
67. Stenger JE, Mayr JA, Mann K and Tegtmeyer P (1992) Formation of stable homotetramers and multiples of tetramers. Mol Carcinogen 5: 102-106
68. Subler MA, Martin DW and Deb S (1992) Inhibition of viral and cellular promoters by human wild-type p53. J Virol 66: 6164-6170
69. Vogelstein B and Kinzler KW (1992) p53 Function and Dysfunction. Cell 70: 523-526
70. World Health Organization (1982) The World Health Organization histologic typing of lung tumours. Am J Clin Path 77: 123-136
71. Wu X, Bayle JH, Olson D and Levine AJ (1993) The p53-mdm2 autoregulatory feedback loop. Genes Dev 7: 1126-1132
72. Xiao ZX, Chen J, Levine AJ, Modjtahedi N, Xing J, Sellers WR and Livingston DM (1995) Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 375: 694-698
73. Zakutt-Houri R, Bienz-Tadmor H, Givol D and Oren M (1985) Human p.53 cellular tumour antigen: cDNA sequence and expression in COS cells. EMBO J 4: 1251-1255
74. Zambetti GP and Levine AJ (1993) A comparison of the biological activities of wild-type and mutant p53. FASEB J 7: 855-865
75. Zauberman A, Flusberg D, Haupt Y, Barak Y and Oren M (1995a) A functional p53-responsive intronic promoter is contained within the human mdm2 gene. Nucleic Acids Res 23: 2584-2592
76. Zauberman A, Lubp A and Oren M (1995b) Identification of p53 target genes through immune selection of genomic DNA: The cyclin G gene contains two distinct p53 binding sites. Oncogene 10: 2361-2366
77. Zhang W, Funk WD, Wright WE, Shay JW and Deisseroth AB (1993a) Novel DNA binding of p53 mutants and their role in transcriptional activation. Oncogene 8: 2555-2559
78. Zhang W, Shay JW and Deisseroth A (1993b) Inactive p53 mutants may enhance the transcriptional activity of wt p53. Cancer Res 53: 4772-4775
79. Zhang W, Randhawa GS, Gau J-P, Shay JW and Deisseroth AB (1995) The first intron of human H-ras is regulated by p53: Mediation of specific activation by a p53-binding element. Int J Oncol 7: 1021-1028